Kailera Therapeutics (NASDAQ:KLRA) Trading Down 5.5% – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) was down 5.5% on Monday . The company traded as low as $12.13 and last traded at $12.13. 287,447 shares were traded during mid-day trading, a decline of 62% from the average session volume of 757,702 shares. The stock had previously closed at $12.83.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Weiss Ratings began coverage on Kailera Therapeutics in a research report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 5.6%

The stock has a market capitalization of $1.57 billion and a PE ratio of -0.00. The stock’s fifty day moving average price is $17.03.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Trading of Kailera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Atlas Venture Life Science Advisors LLC bought a new position in Kailera Therapeutics in the second quarter valued at about $113,923,000. Wellington Management Group LLP acquired a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $64,308,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $24,233,000. Squarepoint Ops LLC bought a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at approximately $993,000. Finally, Tidal Investments LLC bought a new stake in shares of Kailera Therapeutics during the second quarter worth $309,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.